Poland· PL-100347574
Tranexamic acid Accord
A tranexamic acid product containing acidum tranexamicum, registered in Poland by Accord Healthcare Polska Sp. z o.o.. The same ATC class is registered in 15 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Tranexamic acid is registered in 15 of 19 countries.
Countries holding a registration under ATC B02AA02 (tranexamic acid), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Tranexamic acid · ATC B02AA02
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tranexamic acid costs, country by country.
Normalised to the WHO defined daily dose (2 g), the median price runs from $1.69 in Italy to $34.44 in Switzerland — a ×20 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Tranexamic acid · price per daily dose (2 g)
USD · FX 28 Sept 2026
- CH Switzerland$34.44
- IT Italy$1.69
The record
At a glance
URPL (Poland)- Active substance
- Acidum tranexamicum
- Manufacturer
- Accord Healthcare Polska Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- B02AA02
- ATC class
- Tranexamic acid
- Defined daily dose
- 2 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 6
- gtin05909991313678
- gtin05909991313685
- gtin05909991313692
- gtin05909991313708
- gtin05909991313715
- gtin05909991313722
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
45 interactions on record for tranexamic acid.
Graded by severity as the source publishes them — 36 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tranexamic acid · interactions on record
45 records
- 36 severe
- 8 moderate
- 1 minor
Most severe, free to view
- Faktor VIII-Inhibitor Bypass Aktivität - FEIBAB02BD03severe
- EstradiolD11AX34severe
- IUP aus Plastik mit GestagenG02BA03severe
- Levonorgestrel and ethinylestradiolG03AA07severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Tranexamic acid in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEXACYLCHEPLAPHARM Arzneimittel GmbH, Greifswald
- SwitzerlandTranexam Labatec 1000 mg/10 mL, solution injectableLabatec Pharma SA
- BelgiumExacyl 500 mg/5 mlCheplapharm Arzneimittel
- SwedenMedsamic 100 mg/ml Injektionsvätska, lösningMedochemie Ltd
- SpainACIDO TRANEXAMICO AUROVITAS 100 MG/ML SOLUCION INYECTABLE EFGAurovitas Spain, S.A.U.
- ItalyACIDO TRANEXAMICO AUROBINDOEUGIA PHARMA (MALTA) LIMITED
- FinlandCyklokapronPharmacia Oy
- NorwayPilexamPilum Pharma A/S
Authorised across Europe · EMA
The same active substance is authorised in 29 EEA countries. Names it is sold under:
- Austria · Cyklokapron, Tranexamsäure Baxter
- Belgium · Acide Tranexamique Kabi, Cyklokapron
- Bulgaria · Медокапрон, Т-Капрон
- Cyprus · Azeptil, Medsamic
- Czechia · Exacyl, Tranexamic Acid Accord
- Germany · Cyklokapron, Cyklokapron-Injektionslösung
- Denmark · Cyklokapron, Cyklonova
- Estonia · Cyklokapron, Medsamic
- Spain · Ácido Tranexámico Baxter, Ácido Tranexámico Viatris
- Finland · Caprilon, Cyklokapron
- France · Acide Tranexamique Accord, Acide Tranexamique Aguettant
- United Kingdom (Northern Ireland) · Cyklo-F, Cyklokapron
- Greece · Tranexamic Acid /Kabi, Tranexamic Acid Baxter
- Croatia · Medsamic, Trenolk
- Hungary · Exacyl, Nimra
- Ireland · Cyklokapron, Tranexamic Acid Accord Healthcare Ireland
- Iceland · Cyklokapron, Tranexamsyre Pfizer
- Italy · Acido Tranexamico Adamed, Acido Tranexamico Aurobindo
- Lithuania · Haixa, Tranexamic Acid Baxter
- Luxembourg · Exacyl, Tranexamsäure Dr. Eberth
- Latvia · Cyklokapron, Haixa
- Malta · Azeptil, Medsamic
- Netherlands · Cyklokapron, Nexag
- Norway · Cyklokapron, Pilexam
- Portugal · Ácido Tranexâmico A.Forall, Ácido Tranexâmico Accord
- Romania · Acid Tranexamic Kabi, Medsamic
- Sweden · Cyklo-F, Cyklokapron
- Slovenia · Medsamic, Trenolk
- Slovakia · Medsamic, Tranexamic Acid Kabi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d6379c8d-6a4d-4e22-ad2c-2a4a8ef7fe86 GET /v1/drugs/d6379c8d-6a4d-4e22-ad2c-2a4a8ef7fe86?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "100 mg/ml",
"packaging": "05909991313678 ¦ Rp ¦ 120233\n1 amp. 10 ml\n05909991313685 ¦ Rp ¦ 120234\n1 amp. 5 ml\n05909991313692 ¦ Rp ¦ 120235\n5 amp. 5 ml\n05909991313708 ¦ Rp ¦ 120236\n5 amp. 10 ml\n05909991313715 ¦ Rp ¦ 120237\n10 amp. 10 ml\n05909991313722 ¦ Rp ¦ 120238\n10 amp. 5 ml",
"substance": "Acidum tranexamicum 100 mg/ml",
"common_name": "Acidum tranexamicum",
"pl_product_id": "100347574",
"pozwolenie_nr": "23723",
"auth_procedure": "DCP",
"authorisation_validity": "Bezterminowe"
}See everything about tranexamic acid.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.